Objective: To improve quality-of-life and health care delivery to patients receiving ureteral stents.
Specific Aims: Evaluate the feasibility, practicality, and qualitative outcomes of utilizing intra-nasal ketorolac in patients with indwelling ureteral stents (Phase I), followed by a randomized trial comparing two non-steroidal anti-inflammatory drugs, intra-nasal Ketorolac versus oral Diclofenac.
Hypotheses: Due to its favorable pharmacokinetics in relieving acute pain, investigators expect improved pain scores and a lower rate of unplanned clinical encounters in patients receiving intra-nasal ketorolac compared to those taking oral diclofenac following ureteroscopic surgery for urolithiasis.
Study Rationale: Following ureteroscopic management of urolithiasis, patient with indwelling ureter stents have higher levels of discomfort compared to those without a ureter stent. Prior studies showed that intramuscular Ketorolac at time of ureter stent removal decreased the incidence of unplanned clinical encounters. Furthermore, onset of analgesic effect by intra-nasal ketorolac is faster than its oral form, and similar its intramuscular and intravenous counterparts.

开始日期2024-11-01

申办/合作机构

The University of Texas Southwestern Medical Center

[+1]

IRCT20220706055402N6 / Recruiting临床3期IIT

effect of ketorolac wound infiltration on caesarian post operative pain

开始日期2024-10-12

申办/合作机构-

IRCT20120215009014N531 / Recruiting临床3期IIT

A comparison of the analgesic effect of ketorolac, morphine and Apotel in head trauma patients: a triple-blind randomized clinical trial

开始日期2024-10-11

申办/合作机构

Hamedan University of Medical Sciences

100 项与酮咯酸相关的临床结果

登录后查看更多信息

100 项与酮咯酸相关的转化医学

登录后查看更多信息

100 项与酮咯酸相关的专利（医药）

登录后查看更多信息

3,308

项与酮咯酸相关的文献（医药）

2024-11-01·The Laryngoscope

Post‐Tonsillectomy Bleeding and Analgesic Use Before and After the FDA Boxed Warning Against Codeine

Article

作者: Chalamgari, Anjalika ; Carr, Michele M. ; Vijay, Arunima ; Cottone, Chloe

ObjectiveThe aim of this study was to investigate the trends in post‐tonsillectomy analgesic utility and incidence of post‐tonsillectomy hemorrhage before and after the 2013 FDA Boxed Warning against codeine use after pediatric tonsillectomy.MethodsA retrospective study was conducted using TriNetX. A search for patients up to 18 years from 2008 to 2022 within the US Collaborative Network identified 15,648,542 subjects. CPT and ICD‐10 codes were used to identify children who experienced post‐tonsillectomy hemorrhage within 14 days of a tonsillectomy. Analgesics given within 14 days of tonsillectomy were tabulated annually from 2008 to 2022, including codeine, ibuprofen, acetaminophen, oxycodone, ketorolac, and hydrocodone. Bleeding percentage and analgesic utility were grouped into events before and after 2013.ResultsMean age at tonsillectomy was 5.6 years (SD = 3.0). Before 2013, the median percentage of children who experienced postoperative bleeding was 1.8% with 0.73% returning to the OR for bleeding control. After 2013, the median percentage of children who experienced postoperative bleeding was 2.4% (p = 0.029), and 0.99% returned to the OR (p = 0.008). Use of post‐tonsillectomy codeine fell from 10.4% to 0.5% (p = 0.003) whereas ibuprofen rose from 2.0% to 63.9% (p = <0.001), acetaminophen from 42.8% to 77.2% (p = <0.001), ketorolac from 1.2% to 9.2% (p = <0.001), and oxycodone from 2.0% to 30.9% (p = <0.001). No change was detected in use of hydrocodone.ConclusionAnalgesics used post‐tonsillectomy in children have changed since the FDA Boxed Warning against codeine. There has been a small but statistically significant increase in post‐tonsillectomy bleeding.Level of Evidence4 Laryngoscope, 134:4783–4788, 2024

2024-11-01·Journal of Pediatric Orthopaedics

Efficacy of a Multimodal Surgical Site Injection for Postoperative Pain Control in Pediatric Patients With Cerebral Palsy Undergoing Hip Reconstruction: A Randomized Controlled Trial

Article

作者: Young, Bailey ; Swaroop, Vineeta T. ; Thompson, Rachel M. ; Greig, Danielle ; Sun, Christina A. ; McBride, Daniel ; Klomhaus, Alexandra

Background:One in 4 children with cerebral palsy (CP) will undergo orthopaedic surgery during their childhood. Despite its ubiquity, postoperative pain control has been poorly studied in this patient population. Moreover, poor pain management has been associated with adverse surgical outcomes. Multimodal analgesic injections have been well studied in the adult population, demonstrating safety and efficacy in reducing postoperative pain and narcotic consumption, but this modality has not been studied in pediatric patients undergoing similarly complex procedures. The objective of this study was to evaluate the efficacy of a multimodal surgical site injection for postoperative pain control following operative management of hip dysplasia in patients with CP.Methods:After obtaining IRB approval, a multicenter, randomized double-blind placebo control trial was completed. Patients below 18 years old with a diagnosis of CP who were scheduled for varus derotation osteotomy (VDRO) of the proximal femur were randomized to receive a surgical-site injection with either a combination of ropivacaine (3 mg/kg), epinephrine (0.5 mg), and ketorolac (0.5 mg/kg) (experimental group) or normal saline (control). All included patients had identical postoperative care, including immobilization, physical therapy, and standardized, multimodal postoperative pain control. Pain scores and narcotic consumption were recorded at regular intervals and compared between groups utilizing two-tailed t test or a nonparametric Mann-Whitney test for quantitative variables and a Fischer exact test for categorical variables.Results:Thirty-four patients were included, evenly divided between study arms. There were no significant differences in demographic variables, gross motor function classification system (GMFCS), comorbidities, preoperative radiographic parameters, or concomitant surgeries between groups. Patients in the experimental group required significantly lower narcotic medications at all postoperative time points from PACU until hospital discharge compared with controls (0.41 ± 0.42 vs. 1.87 ± 2.05 total morphine mEQ/kg, P=0.01). Similarly, patients in the experimental group were found to have significantly lower pain scores throughout their hospital stays compared with controls (1.0 ± 0.6 vs. 2.4 ± 1.1 mean pain score, P<0.001). There were no significant differences in operative time, OR time, blood transfusion requirements or hospital length of stay between groups. There were no adverse medication reactions or injection site complications in either group.Conclusions:In patients with CP undergoing hip reconstruction, surgical-site injection with a multimodal analgesic combination improves pain control and reduces narcotic consumption in the early postoperative period with no observed adverse effects.Significance:Local multimodal analgesic injections should be adopted as part of standard multimodal pain control in this patient population for all osseous surgeries.Level of Evidence:Level I—therapeutic.

2024-10-22·World neurosurgery

Safety and Efficacy of Ketorolac After Craniotomy for Tumor Resection.

Article

作者: Ali, Madiha ; Chen, Si ; Miller, Patricia ; Reilly, Thomas ; Ebrahim, Ghaidaa ; Sorrentino, Zachary ; Sriram, Sai ; Rahman, Maryam ; Koch, Matthew ; Ghiaseddin, Ashley ; Chowdhury, Baker

OBJECTIVEPostoperative pain is the most common undesirable outcome after neurosurgery. Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) which is administered parenterally and carries a theoretical increased risk of bleeding. Our study aims to determine whether ketorolac after craniotomy for tumor resection significantly changes the rate of postoperative adverse events, adequately controls pain, and decreases concurrent narcotic usage.METHODSWe performed a retrospective chart review of all adult patients who underwent craniotomy for brain tumor resection from 2013 to 2022. Analysis of patients who received ketorolac and those who did not in the post-operative period were compared for adverse events associated with ketorolac use. Secondary outcomes included patient-reported pain scores and postoperative opioid usage.RESULTS1,114 patients were included, of which 70 received ketorolac in the postoperative period. Patients who received ketorolac often received it after narcotics failed to provide adequate pain control. Patients receiving ketorolac were younger (p=0.001) and had a lower comorbidity index (p=0.041) compared to the non-ketorolac group. Patients receiving ketorolac did not experience a significantly increased rate of bleeding events (p=0.850). Patients recieving ketorolac had significantly higher baseline levels of pain (p=0.018) and opioid usage (p=0.047). When matched for chronic comorbidities including pain disorders, the ketorolac group only displayed higher levels of pain early in the postoperative course (POD 0-1) but not in latter part of the initial postoperative period.CONCLUSIONSKetorolac is a safe and effective option for pain control after craniotomy for tumor resection. Prospective data is needed to better validate these retrospective observations.

项与酮咯酸相关的新闻（医药）

2024-02-26

·信狐药迅

兆科痤疮新药阿达帕林克林霉素凝胶，卓和中药新药风叶咳喘平口服液获批文 | 新获批（2.19-2.25）

每周药品注册受理数据，分门别类呈现，一目了然。（2.19-2.25）新药上市申请药品名称企业名称分类受理号阿达帕林盐酸克林霉素复方凝胶兆科(广州)眼科药物有限公司2.3CXHS2100002特立帕肽注射液上海联合赛尔生物工程有限公司3.3CXSS2200068新药临床申请药品名称企业名称分类受理号ADC189颗粒嘉兴安谛康生物科技有限公司1CXHL2301377BEBT-109胶囊广州必贝特医药股份有限公司1CXHL2301363BEBT-109胶囊广州必贝特医药股份有限公司1CXHL2301364GLB-001胶囊杭州格博生物医药有限公司1CXHL2301360GLB-001胶囊杭州格博生物医药有限公司1CXHL2301361GLB-001胶囊杭州格博生物医药有限公司1CXHL2301362HP537片海创药业股份有限公司1CXHL2301351HP537片海创药业股份有限公司1CXHL2301352HRS-1167片江苏恒瑞医药股份有限公司1CXHL2301200JMKX003561颗粒浙江杭煜制药有限公司1CXHL2301356JMKX003561颗粒浙江杭煜制药有限公司1CXHL2301357JP-1366片丽珠集团丽珠医药研究所1CXHL2301335JW202232吸入气雾剂山东泰合医药科技有限公司2.2CXHL2301319TL938胶囊苏州韬略生物科技股份有限公司1CXHL2301355盐酸安罗替尼胶囊正大天晴药业集团股份有限公司2.4CXHL2301373盐酸安罗替尼胶囊正大天晴药业集团股份有限公司2.4CXHL2301374盐酸安罗替尼胶囊正大天晴药业集团股份有限公司2.4CXHL2301375aT19注射液北京永泰瑞科生物科技有限公司1CXSL2300808JWK001注射液成都金唯科生物科技有限公司1CXSL2300827QX007N注射液江苏荃信生物医药股份有限公司1CXSL2300850WG1025北京唯源立康生物科技股份有限公司1CXSL2300809注射用HS-20089上海翰森生物医药科技有限公司1CXSL2300849注射用PRO1107普方生物制药(苏州)有限公司1CXSL2300847注射用SIBP-A17上海生物制品研究所有限责任公司1CXSL2300851重组带状疱疹疫苗(CHO细胞)上海生物制品研究所有限责任公司1.3CXSL2300817重组带状疱疹疫苗(CHO细胞)上海生物制品研究所有限责任公司1.3CXSL2300818仿制药申请药品名称企业名称分类受理号丙泊酚中/长链脂肪乳注射液石家庄四药有限公司4CYHS2201195丙泊酚中/长链脂肪乳注射液石家庄四药有限公司4CYHS2201196乙酰半胱氨酸泡腾片宁波美诺华天康药业有限公司4CYHS2201771乙酰半胱氨酸泡腾片江苏安必生制药有限公司4CYHS2201683低钙腹膜透析液(乳酸盐-G1.5)上海华源安徽锦辉制药有限公司4CYHS2201024低钙腹膜透析液(乳酸盐-G2.5)上海华源安徽锦辉制药有限公司4CYHS2201009依托考昔片山西同达药业有限公司4CYHS2200527依托考昔片山西同达药业有限公司4CYHS2200528依替巴肽注射液沈阳双鼎制药有限公司3CYHS2200579利伐沙班片天津力生制药股份有限公司4CYHS2201017利伐沙班片天津力生制药股份有限公司4CYHS2201018利伐沙班片天津力生制药股份有限公司4CYHS2201016利奈唑胺葡萄糖注射液江苏晨牌药业集团股份有限公司4CYHS2200161去氧肾上腺素酮咯酸溶液苏州朗易生物医药研究有限公司3CYHS2301443吡拉西坦注射液华夏生生药业(北京)有限公司3CYHS2201887吡拉西坦注射液华夏生生药业(北京)有限公司3CYHS2201888吲哚布芬片仁合益康集团有限公司3CYHS2301213吸入用乙酰半胱氨酸溶液云南龙海天然植物药业有限公司4CYHS2201984呋塞米口服液成都倍特得诺药业有限公司3CYHS2200938地夸磷索钠滴眼液成都普什制药有限公司4CYHS2201668地屈孕酮片杭州和泽坤元药业有限公司4CYHS2201435头孢地尼颗粒海南葫芦娃药业集团股份有限公司4CYHS2200370头孢托仑匹酯颗粒北京诚济制药股份有限公司4CYHS2302749奥硝唑注射液西安信百欣医药科技有限公司3CYHS2201249奥硝唑注射液西安信百欣医药科技有限公司3CYHS2201250对乙酰氨基酚维生素C泡腾片山东新鲁医药科技有限公司3CYHS2301569左乙拉西坦缓释片华润赛科药业有限责任公司3CYHS2200992左乙拉西坦缓释片华润赛科药业有限责任公司3CYHS2200993己酮可可碱注射液山东泰合医药科技有限公司3CYHS2201467异硫蓝注射液广东和博制药有限公司3CYHS2200409枸橼酸托法替布片黑龙江珍宝岛药业股份有限公司4CYHS2102173氟维司群注射液轩竹生物科技股份有限公司4CYHS2201150氢溴酸伏硫西汀片辰欣药业股份有限公司4CYHS2201399氢溴酸伏硫西汀片辰欣药业股份有限公司4CYHS2201400氧湖南昇宇科技开发有限公司4CYHS2300752氨磺必利口服溶液山东朗诺制药有限公司3CYHS2201774氯化钾注射液广州艾奇西医药科技有限公司3CYHS2201393氯化钾注射液广州艾奇西医药科技有限公司3CYHS2201394氯化钾注射液海南紫程众投生物科技有限公司3CYHS2201317氯化钾颗粒杭州和泽坤元药业有限公司3CYHS2201694氯替泼诺妥布霉素滴眼液天津金耀药业有限公司4CYHS2300842氯雷他定糖浆河北三禾实创生物科技有限公司4CYHS2300789氯雷他定糖浆河北三禾实创生物科技有限公司4CYHS2300790注射用头孢他啶阿维巴坦钠上海欣峰制药有限公司4CYHS2200952注射用盐酸瑞芬太尼宜昌人福药业有限责任公司3CYHS2202145注射用盐酸瑞芬太尼宜昌人福药业有限责任公司3CYHS2202146注射用盐酸瑞芬太尼宜昌人福药业有限责任公司3CYHS2202147注射用盐酸罗沙替丁醋酸酯北京品尚品医药科技有限公司3CYHS2200371注射用艾司奥美拉唑钠重庆中创科医药有限公司4CYHS2201720注射用阿扎胞苷齐鲁制药(海南)有限公司4CYHS2200759盐酸帕罗西汀片江苏睿实生物科技有限公司4CYHS2201063盐酸氨溴索口服溶液南京卡文迪许生物工程技术有限公司4CYHS2300569盐酸特比萘芬喷雾剂华润三九医药股份有限公司4CYHS2200820盐酸特比萘芬喷雾剂浙江恒研医药科技有限公司4CYHS2200544盐酸纳洛酮注射液东阳祥昇医药科技有限公司3CYHS2201420盐酸达泊西汀片江苏万高药业股份有限公司4CYHS2201054盐酸鲁拉西酮片辰欣药业股份有限公司4CYHS2102298硝酸甘油葡萄糖注射液仁合益康集团有限公司3CYHS2301226硝酸甘油葡萄糖注射液仁合益康集团有限公司3CYHS2301227硫酸氨基葡萄糖胶囊青岛百洋制药有限公司4CYHS2201008硫酸特布他林注射液成都利尔药业有限公司3CYHS2200341硫酸镁注射液北京民康百草医药科技有限公司3CYHS2201519碳酸氢钠林格注射液石家庄四药有限公司3CYHS2201309磷酸奥司他韦胶囊吉林敖东洮南药业股份有限公司4CYHS2201343磷酸奥司他韦胶囊吉林敖东洮南药业股份有限公司4CYHS2201344磷酸奥司他韦胶囊吉林敖东洮南药业股份有限公司4CYHS2201345维格列汀片惠升生物制药股份有限公司4CYHS2201303罗库溴铵注射液吉林振澳制药有限公司4CYHS2200841罗库溴铵注射液吉林振澳制药有限公司4CYHS2200842美阿沙坦钾片仁合益康集团有限公司4CYHS2301049美阿沙坦钾片仁合益康集团有限公司4CYHS2301050聚乙烯醇滴眼液远大医药(中国)有限公司3CYHS2300885舒更葡糖钠注射液海南睿智医药科技投资有限公司4CYHS2200321西格列汀二甲双胍缓释片上海安必生制药技术有限公司3CYHS2200155西洛他唑片北京福元医药股份有限公司3CYHS2201576酒石酸溴莫尼定滴眼液北京诺思兰德生物技术股份有限公司4CYHS2200665酮咯酸氨丁三醇注射液江苏明圣康源药业有限公司3CYHS2303616酮咯酸氨丁三醇注射液成都瑞尔医药科技有限公司3CYHS2300791铝碳酸镁混悬液四川益生智同医药生物科技发展有限公司3CYHS2200912长链脂肪乳注射液(OO)成都国为生物医药有限公司4CYHS2200467阿司匹林肠溶片江苏万高药业股份有限公司4CYHS2201656阿哌沙班片华润双鹤药业股份有限公司4CYHS2201597阿立哌唑口服溶液山东百诺医药股份有限公司3CYHS2201251骨化三醇软胶囊江苏中治制药有限公司4CYHS2201535进口申请药品名称企业名称分类受理号Camonsertib胶囊F.Hoffmann-La Roche Ltd.1JXHL2300307CagriSema注射液Novo Nordisk A/S1JXSL2300221CagriSema注射液Novo Nordisk A/S1JXSL2300222CagriSema注射液Novo Nordisk A/S1JXSL2300223CagriSema注射液Novo Nordisk A/S1JXSL2300224CagriSema注射液Novo Nordisk A/S1JXSL2300225MK-7240注射液Merck Sharp & Dohme LLC1JXSL2300219MK-7240注射用浓溶液Merck Sharp & Dohme LLC1JXSL2300220SAR443765注射液Sanofi-Aventis Recherche & Developpement1JXSL2300216注射用重组单链人凝血因子VIIICSL Behring GmbH3.1JXSL2300208注射用重组单链人凝血因子VIIICSL Behring GmbH3.1JXSL2300209注射用重组单链人凝血因子VIIICSL Behring GmbH3.1JXSL2300210注射用重组单链人凝血因子VIIICSL Behring GmbH3.1JXSL2300211注射用重组单链人凝血因子VIIICSL Behring GmbH3.1JXSL2300212注射用重组单链人凝血因子VIIICSL Behring GmbH3.1JXSL2300213注射用重组单链人凝血因子VIIICSL Behring GmbH3.1JXSL2300214恩曲替尼胶囊Roche Pharma (Schweiz) AG5.1JXHS2300045恩曲替尼胶囊Roche Pharma (Schweiz) AG5.1JXHS2300046硫酸羟氯喹片Amneal EU, Limited5.2JYHS2300128醋酸锌片Nobelpharma Co.,Ltd.5.1JXHS2300017醋酸锌片Nobelpharma Co.,Ltd.5.1JXHS2300018珂罗利单抗注射液Roche Pharma (Schweiz) AG1JXSS2200031中药相关申请药品名称企业名称分类受理号风叶咳喘平口服液卓和药业集团股份有限公司1.1CXZS2200014注：灰色字体部分结论为不批准或收到通知件；

申请上市抗体药物偶联物疫苗

2024-02-23

·生物探索

Circulation | 南京医科大学季勇/谢利平/王东进发现加重主动脉瘤和夹层的新机理

引言S-亚硝基化(SNO)是一种典型的基于氧化还原的翻译后修饰，与心血管疾病有关。主动脉瘤和夹层是目前尚无有效治疗方法的高危心血管疾病。2024年2月15日，南京医科大学季勇、谢利平及王东进共同通讯在Circulation (IF 38)在线发表题为“S-Nitrosylation of Septin2 Exacerbates Aortic Aneurysm and Dissection by Coupling the TIAM1-RAC1 Axis in Macrophages”的研究论文，该研究表明巨噬细胞中Septin2的S-亚硝基化通过偶联TIAM1-RAC1轴加重主动脉瘤和夹层。在接受主动脉夹层手术的患者和注射血管紧张素II的Apoe-/-小鼠的主动脉组织中，Septin2被鉴定为S-亚硝基化的半胱氨酸111 (Cys111)。SNO-Septin2被证实可促进主动脉瘤和夹层的发展。通过RNA测序，证实巨噬细胞中的SNO-Septin2可加剧主动脉瘤血管炎症和细胞外基质降解。接下来，TIAM1 (T淋巴瘤侵袭和转移诱导蛋白1)被确定为SNO-Septin2的靶蛋白。机制上，与未修饰的Septin2相比，SNO-Septin2减少了与TIAM1的相互作用，激活了TIAM1- RAC1轴及其相关的核因子-κB信号通路，导致巨噬细胞介导的炎症和细胞外基质降解更强。一致地，R-Ketorolac和NSC23766治疗通过抑制TIAM1-RAC1轴来保护主动脉瘤和夹层。总之，SNO-Septin2通过偶联巨噬细胞中的TIAM1-RAC1轴，激活核因子-κB信号通路依赖性炎症和细胞外基质降解，驱动主动脉瘤和夹层。因此，R-Ketorolac或NSC23766对RAC1的药理学阻断可能是治疗主动脉瘤和夹层的潜在方法。主动脉瘤和主动脉夹层是高死亡率的心血管疾病。主动脉瘤的特征是主动脉局部或弥漫性扩张，这逐渐增加了急性主动脉夹层的风险。主动脉夹层被定义为内膜破裂，导致主动脉壁层分离，随后形成真腔和假腔。尽管在影像学和血管开放修复和血管内修复方面取得了重大进展，但有效的药物治疗仍然不可用。巨噬细胞积聚在动脉瘤主壁上，通过影响细胞外基质(ECM)降解和炎症，促进了动脉瘤和夹层的发生研究发现，浸润于主动脉瘤血管壁及夹层的大量巨噬细胞高度表达诱导型一氧化氮(NO)合成酶(iNOS)，可催化产生大量NO，并通过蛋白S-亚硝基化(SNO)发挥多种病理生理作用。SNO是将NO部分可逆的共价加成到半胱氨酸硫醇上，形成S-亚硝基蛋白，参与心脏肥厚、心脏纤维化、动脉粥样硬化等多种心血管疾病的发病。因此，SNO可能发生在主动脉瘤及夹层血管组织中iNOS高表达并参与主动脉瘤及夹层的巨噬细胞中。Cys111突变的Septin2减轻主动脉瘤（Credit: Circulation）Septin2属于Septin家族。Septin是一个高度保守的蛋白家族，在细胞分裂、细胞内物质运输、细胞周期调节和细胞凋亡中被越来越多地认为是细胞骨架的一个新组成部分。已被证明在阿尔茨海默病、癌症、感染和系统性红斑狼疮中发挥重要作用Septin2参与维持内皮细胞连接和内皮完整性。Septin2还可以通过增强内皮细胞的迁移来促进血管生成。然而，Septin2在主动脉瘤和夹层中的作用尚不清楚。该研究证实了在半胱氨酸111 (Cys111)位点Septin2的SNO加重血管紧张素II (Ang II)诱导的主动脉瘤和β-氨基丙腈(BAPN)诱导的主动脉瘤和夹层。机制上，SNO-Septin2减少其与巨噬细胞中TIAM1 (T淋巴瘤侵袭和转移诱导蛋白1)的相互作用，激活TIAM1RAC1 (Ras相关的C3肉毒毒素底物1)轴及其相关的核因子-κB (NF-κB)信号通路，促进更强的炎症反应和ECM降解。总之，这些发现表明SNO-Septin2可能是动脉瘤和夹层的治疗靶点。原文链接https://doi.org/10.1161/CIRCULATIONAHA.123.066404责编|探索君排版|探索君文章来源|“iNature”End往期精选围观一文读透细胞死亡(Cell Death) | 24年Cell重磅综述（长文收藏版）热文Nature | 破除传统：为何我们需要重新思考肿瘤的命名方式热文Nature | 2024年值得关注的七项技术热文Nature | 自身免疫性疾病能被治愈吗？科学家们终于看到了希望热文Nature | 癌症与神经系统的致命舞蹈

2024-02-13

·BioSpace

Yinuoke publication demonstrates a new orally delivered molecule that reverses cancer cachexia and increases survival using in vivo models

Yinuoke, a biopharmaceutical company pioneering breakthrough therapeutics for late-stage cancer patients announced today the publication of a manuscript in the peer-reviewed Journal of Cachexia, Sarcopenia and Muscle demonstrating the effectiveness of a new compound in alleviating cachexia and increasing the survival of tumor-bearing mice in a T-cell dependent manner. Cancer cachexia, a devastating tumor-induced immune disorder leading to body wasting and reduced tolerability to therapeutics, occurs in 80% of all cancer patients and causes 25% of deaths. Previous attempts to treat cachexia have failed due to lack of efficacy in stabilizing patient weight and strength. Yinuoke treats cachexia as a tumor-driven autoimmune disorder rather than a metabolic condition. YNK105 reduces systemic inflammation without the toxic side effects caused by NSAIDS that limit its use. The data shows a significant improvement in cachexigenic tumor-bearing mice in overall survival, increases in body, fat, and muscle weight, and reductions in plasma IL-6 and tissue- derived Stat3. Most impressively, cachectic mice achieved a 100% survival rate with a combination treatment of YNK105 and chemotherapy. “This research is the first demonstration that severe cachexia can be halted and reversed”, said Dr. Lingbing Zhang, founder and CEO of Yinuoke. “The ability to reverse cachexia expands the options for late-stage cancer patients to extend survival and live a higher quality of life. Reversing cachexia requires modulating the immune system’s inflammatory response for longer than an NSAID will allow. We identified R-ketorolac as a potential treatment for cachexia and now have significant evidence to support a superior efficacy and safety pro to current approaches using GDF-15 inhibitors or Anamorelin.” “YNK105 has the potential to be a breakthrough treatment for cancer cachexia that I am excited to bring into the clinic,” said Dr. Andrew Hendifar of Cedars-Sinai. “Pancreatic cancer patients are highly susceptible to cachexia and treatment outcomes are severely impacted. Getting control of cachexia is critical for overall survival of patients with pancreatic cancer and especially for stage 4 and late diagnosed patients. These early studies support moving this program into clinical trials.” The research appearing in the February 1st issue of the Journal of Cachexia, Sarcopenia and Muscle is led by Dr. Martina Schweiger and a team of scientists at the Institute of Molecular Biosciences, University of Graz, Austria. About Yinuoke Yinuoke is on a mission to save lives and conquer late-stage cancer through groundbreaking science and the development of first-in-class therapies where no options currently exist. Our vision is to revolutionize late-stage cancer by pushing boundaries and transforming it from a terminal disease to a manageable lifelong condition. Through innovative approaches and tailored treatments, we aim to empower patients with new possibilities for long-term remission and improved quality of life. For inquiries on partnering and investing please contact Suzanne Kennedy at skennedy@yinuokeus.com.

临床结果

100 项与酮咯酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08104	酮咯酸	M01AB15	DB00465

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
术后疼痛	临床3期	-	Neumentum, Inc.初创企业	-
术后炎症	临床1期	美国	Layerbio, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AAO2022	N/A	眼科外科手术	-	Epinephrine alone	(憲齋構鏇構壓衊願鹹憲) = 築構衊膚構鏇鑰齋憲鹽膚壓廠積糧艱艱糧網繭 (範鑰醖膚憲獵鏇獵衊願 ) 更多	-	2022-09-29
				Omidria (intracameral phenylephrine and ketorolac)	(憲齋構鏇構壓衊願鹹憲) = 觸鑰齋製構觸糧獵顧繭膚壓廠積糧艱艱糧網繭 (範鑰醖膚憲獵鏇獵衊願 ) 更多
TCTR20200909006 (Pubmed) 人工标引	临床3期	德凯尔费恩病	60	Lidocaine+Adrenaline+Ketorolac	壓鑰淵繭艱鹹鹹鏇獵蓋(壓醖壓簾鹽鹹艱壓積壓) = 顧網膚蓋鬱鏇積獵蓋鬱積鑰範壓醖壓衊壓鏇遞 (觸遞選窪築網鹹願餘獵, 2.0)	不佳	2022-09-01
				Lidocaine+Adrenaline+Triamcinolone Acetonide	壓鑰淵繭艱鹹鹹鏇獵蓋(壓醖壓簾鹽鹹艱壓積壓) = 餘積遞製淵製獵齋膚構積鑰範壓醖壓衊壓鏇遞 (觸遞選窪築網鹹願餘獵, 3.2)
NCT02358681 (CTgov)	临床3期	偏头痛	59	Placebo, intravenous+Ketorolac, intranasal (Ketorolac, Intranasal)	憲膚蓋鏇鏇獵衊鏇選餘(範積膚鏇獵餘網憲遞鬱) = 鹹夢壓淵餘網構觸齋繭遞鏇觸鏇齋鬱廠蓋顧鑰 (膚廠餘製襯衊願獵簾網, 淵廠衊築鹽鏇淵鏇淵築 ~ 顧網範鬱廠鏇遞廠範膚) 更多	-	2022-01-12
				Placebo, intranasal+Ketorolac, intravenous (Ketorolac, Intravenous)	憲膚蓋鏇鏇獵衊鏇選餘(範積膚鏇獵餘網憲遞鬱) = 蓋構觸鑰鏇夢鹽網廠願遞鏇觸鏇齋鬱廠蓋顧鑰 (膚廠餘製襯衊願獵簾網, 築顧獵顧糧顧淵膚網選 ~ 窪衊願糧齋壓夢網廠顧) 更多
PD26-02 (AUA2021)	N/A	-	-	Ketorolac	鏇鑰齋餘顧衊衊鹹鑰衊(糧膚範獵襯築網願網餘) = 積鑰醖憲積壓膚廠膚範襯醖壓範鹹觸簾齋廠鹽 (窪積顧夢壓顧襯齋窪夢 ) 更多	积极	2021-09-01
				TORADOL (KETOROLAC) (Control)	鏇鑰齋餘顧衊衊鹹鑰衊(糧膚範獵襯築網願網餘) = 齋選窪襯繭顧簾膚壓廠襯醖壓範鹹觸簾齋廠鹽 (窪積顧夢壓顧襯齋窪夢 ) 更多
NCT01806259 (KBCt \| KBC, CTgov)	临床3期	乳腺癌 \| 炎症	203	Ketorolac 30 mg IV (Ketorolac 30 mg)	(範鏇衊襯鑰廠選廠獵構) = 鏇淵觸鹹範鬱醖艱醖顧構獵鹽鬱淵鑰鹽鹹簾醖 (夢淵鏇醖鏇顧餘繭醖願, 鬱遞鹹廠繭製構繭齋鏇 ~ 壓夢繭製夢廠廠鏇顧醖) 更多	-	2020-01-18
				Placebos (NaCl 0.9% 3mL)	(範鏇衊襯鑰廠選廠獵構) = 壓鹹淵遞艱壓鬱壓憲簾構獵鹽鬱淵鑰鹽鹹簾醖 (夢淵鏇醖鏇顧餘繭醖願, 獵獵遞襯窪糧衊壓鹽夢 ~ 網窪鑰壓醖膚鹹範觸艱) 更多
AAO2019	N/A	眼科外科手术	-	Intravenous Ketorolac (IVK)	(積簾繭顧糧衊憲膚鑰窪) = 壓簾廠繭蓋窪觸膚製壓壓壓蓋鏇鑰製選選膚遞 (醖襯繭襯鹽願積願網選 )	积极	2019-10-12
				Ketorolac	(積簾繭顧糧衊憲膚鑰窪) = 廠鑰襯願願鏇鹹膚遞積壓壓蓋鏇鑰製選選膚遞 (醖襯繭襯鹽願積願網選 )
Pubmed	N/A	-	18	S (-) ketorolac	(鑰鏇憲積繭廠繭憲築網) = 衊鑰衊觸壓鏇糧繭製築獵製願衊鏇廠鬱構壓範 (範蓋鏇餘鑰鑰築衊鹽鹽 ) 更多	-	2019-09-01
				R (+) ketorolac	(鑰鏇憲積繭廠繭憲築網) = 鏇選膚遞餘範廠淵糧壓獵製願衊鏇廠鬱構壓範 (範蓋鏇餘鑰鑰築衊鹽鹽 ) 更多
2019 ARVO Annual Meeting (ARVO2019)	N/A	瞳孔散大	214	2.5% phenylephrine, 0.5% tropicamide, and 0.5% ketorolac	(壓觸窪艱糧願鬱範艱鹹) = 糧衊觸網構餘網遞蓋範壓製襯鹹選製蓋餘積鏇 (壓膚築鏇積製構網糧淵 )	-	2019-07-01
				10% phenylephrine, 0.5% tropicamide, and 0.5% ketorolac	(壓觸窪艱糧願鬱範艱鹹) = 築鹹積衊壓範廠齋廠襯壓製襯鹹選製蓋餘積鏇 (壓膚築鏇積製構網糧淵 )
ADA2019	N/A	-	-	Lispro	獵蓋範壓衊鹽網遞鬱憲(顧選糧繭廠鹹積壓構餘) = 齋築顧遞積憲顧糧膚衊築鏇遞廠鏇獵淵膚醖衊 (壓襯糧鹹遞範鹹觸夢壓 ) 更多	-	2019-06-01
				Mixed solution (lispro + ketorolac)	獵蓋範壓衊鹽網遞鬱憲(顧選糧繭廠鹹積壓構餘) = 壓艱願廠艱艱膚膚積獵築鏇遞廠鏇獵淵膚醖衊 (壓襯糧鹹遞範鹹觸夢壓 ) 更多